|
|
||||||||||||||
|
|
|||||||||||||||
a Musculoskeletal
Unit, Freeman Hospital, High Heaton, Newcastle upon Tyne, UK, b Department of
Rheumatology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, UK
Correspondence to: Dr Davidson Email: B.K.S.Davidson{at}ncl.ac.uk
Accepted for publication 24 February 2000
OBJECTIVES
To follow
up a previous report on the lung function of patients with primary
Sjögren's syndrome (SS), and describe the findings having followed
up this cohort for a median duration of 10 years (range 8-12 years).
METHODS
30 patients
fulfilling Fox's criteria for definite or probable primary SS were
assessed within six months of diagnosis and after a median duration of
four and then 10 years by a clinical examination, chest radiograph, and
lung function studies (FEV1, FVC, TLCO, and
KCO).
RESULTS
At baseline,
symptomatic dyspnoea was a common finding, reported by 13/30 patients,
of whom two had evidence of fibrosing alveolitis on plain chest
radiograph. Five patients had a carbon monoxide transfer factor
(TLCO) more than two standardised residuals below the
predicted value. After four years' follow up two further patients
developed radiological fibrotic changes and there were significant
reductions in TLCO (p<0.02) and transfer coefficient (KCO) (p<0.02) compared with the baseline measurements. At
10 years' follow up four patients had died and four were lost to follow up. One patient with fibrosing alveolitis had died from chest
disease. There were no further cases of pulmonary fibrosis identified
on plain chest radiograph. The lung function studies showed no further
deterioration from the results found at year four with significant
improvements in both TLCO (p<0.001) and KCO
(p<0.001). Those patients who were anti-Ro antibody positive had
significantly lower transfer factors than patients with primary SS
without this serological marker (p<0.02).
CONCLUSION
This long
term follow up of lung disease in primary SS is reassuring, and
suggests that most patients do not develop progressive lung disease.
Pulmonary disease occurs predominantly in anti-Ro antibody positive
patients and presents early in the course of the disease.
This article has been cited by other articles:
![]() |
K Haldorsen, K Moen, H Jacobsen, R Jonsson, and J G Brun Exocrine function in primary Sjogren syndrome: natural course and prognostic factors Ann Rheum Dis, July 1, 2008; 67(7): 949 - 954. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. McGrath-Morrow, B. Laube, S.-C. Tzou, C. Cho, J. Cleary, H. Kimura, N. R. Rose, and P. Caturegli IL-12 overexpression in mice as a model for Sjogren lung disease Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L837 - L846. [Abstract] [Full Text] [PDF] |
||||
![]() |
M N Lazarus and D A Isenberg Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome Ann Rheum Dis, July 1, 2005; 64(7): 1062 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Ramos-Casals, A G Tzioufas, and J Font Primary Sjogren's syndrome: new clinical and therapeutic concepts Ann Rheum Dis, March 1, 2005; 64(3): 347 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Wright, R. P. Convery, and N. Liggett Pulmonary involvement in Sjogren's syndrome Rheumatology, May 1, 2003; 42(5): 697 - 698. [Full Text] [PDF] |
||||
![]() |
C V STRIMLAN Pulmonary function in patients with primary Sjogren's syndrome Ann Rheum Dis, April 1, 2001; 60(4): 429a - 429. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |